B7-33
Quick summary
A single-chain peptide derived from relaxin-2 that selectively activates the RXFP1 receptor. Research focus: RXFP1 receptor signaling and fibrosis models. SRP's starting dose for this compound is still pending.
Overview
A single-chain peptide derived from relaxin-2 that selectively activates the RXFP1 receptor. It is studied in fibrosis models.
Looking for research material? Simple Research Peptides lists B7-33 6mg for laboratory research use.
Mechanism
A single-chain relaxin analog that favors one RXFP1 signaling pathway (pERK).
Research areas
- RXFP1 receptor signaling
- fibrosis models
Storage & reconstitution
Supplied as a freeze-dried (lyophilized) powder in a sealed vial. Unopened vials are generally kept cold and away from light. Labs usually reconstitute it with bacteriostatic or sterile water, letting the liquid run down the vial wall and swirling gently instead of shaking. The solution is then kept refrigerated.
Recommended starting dose (low and slow)
| Starting dose | Pending - to be added by SRP |
|---|---|
| Frequency | Pending - to be added by SRP |
| Reconstitution | Pending - to be added by SRP |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Not well characterized in published research.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is B7-33 studied for?
In research it is studied for RXFP1 receptor signaling and fibrosis models. A single-chain relaxin analog that favors one RXFP1 signaling pathway (pERK).
How is B7-33 given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. SRP has not yet published a frequency for this compound.
What amount should a researcher start with?
SRP has not yet published a starting dose for B7-33. Contact SRP before starting any research protocol, and do not guess.
Related peptides
Last updated: October 19, 2026